• Recruiting

NCT04923893: Phase 3 - VRd followed by Cilta-cel Vs VRd f/b Rd - NDMM- (No ASCT planned) CARTITUDE-5

Updated: Sep 25

CARTITUDE-5

Phase 3

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy (CARTITUDE-5)

CARTITUDE-5

The purpose of this study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administration of ciltacabtagene autoleucel (cilta-cel) versus VRd induction followed by Lenalidomide and Dexamethasone (Rd) maintenance in newly diagnosed multiple myeloma participants for whom ASCT is not planned as initial therapy in terms of Progression Free Survival (PFS).


A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy (CARTITUDE-5)


Sponsor

Janssen Research & Development, LLC


Multiple Locations

International Study


Legend Biotech

 

ClinicalTrials.gov Identifier: NCT04923893


Official Title: A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

First Posted : June 11, 2021


Click here for details on ClinicalTrials.gov


A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA versus VRd followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom A... | Global Trial Finder (janssen.com)

 

CART - BCMA : National Cancer Institute

JNJ-68284528 - ciltacabtagene autoleucel


CART

JNJ-68284528

Ciltacabtagene Autoleucel

 

Drug: Bortezomib

Drug: Dexamethasone

Drug: Lenalidomide

Drug: Cilta-cel

Drug: Cyclophosphamide

Drug: Fludarabine

 

1835 Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Vrd Followed By Lenalidomide and Dexamethasone (Rd) Maintenance in Patients with Newly Diagnosed Multiple Myeloma Not Intended for Transplant: A Randomized, Phase 3 Study (CARTITUDE-5)

Program: Oral and Poster Abstracts


Session: 731. Autologous Transplantation: Clinical and Epidemiological: Poster I

Hematology Disease Topics & Pathways:

Clinical Trials, Biological, Clinical Research, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Therapies, Lymphoid Malignancies, Infusion

Saturday, December 11, 2021, 5:30 PM-7:30 PM


Click here for details

 

CARTITUDE Posts:

CARTITUDE-1

CARTITUDE-2

CARTITUDE-4

CARTITUDE-5

CARTITUDE-6

 

- California: University of California San Francisco

- Iowa: University of Iowa Iowa city

- Massachusetts: Dana-Farber Cancer Institute/Harvard Cancer Center Boston

- Massachusetts: Massachusetts General Hospital Boston

- Michigan: Barbara Ann Karmanos Cancer Institute Detroit

- Minnesota: Mayo Clinic Rochester Minnesota

- New York: Memorial Sloan-Kettering Cancer Center New York

- New York: Columbia University Medical Center New York

- North Carolina: Levine Cancer Institute Charlotte

- Pennsylvania: University of Pittsburgh Medical Center

- Texas: UT Southwestern Medical Center Dallas

- Wisconsin: Medical College Of Wisconsin Milwaukee

 

Locations

United States, California

United States, Connecticut

United States, Florida

United States, Iowa

United States, Kansas

United States, Kentucky

United States, Maryland

United States, Massachusetts

United States, Michigan

United States, Minnesota

United States, New York

United States, North Carolina

United States, Pennsylvania

United States, Texas

United States, Virginia

United States, Wisconsin

Canada

Canada, Alberta

Canada, Ontario

Canada, Quebec

Argentina

Brazil

Europe

United Kingdom

France

Germany

Italy

Netherlands

Spain

Austria

Belgium

Czechia

Denmark

Finland

Greece

Hungary

Ireland

Norway

Poland

Portugal

Sweden

Switzerland

Asia

Israel

Korea, Republic of

Japan

Australia

 

RELATED POSTS


NCT03710603: Phase 3 (Perseus) EMN17 - Dara-VRd Vs VRd - Daratumumab, VELCADE, Len, Dex VS VELCADE, Len, Dex in NDMM

Click here for details


NCT03652064: Phase 3 (CEPHEUS) MMY3019 - Dara-VRd Vs VRd - Bortezomib, Lenalidomide, Dex and +/- Daratumumab - NDMM

Click here for details


NCT04566328: Phase 3 (EQUATE) - EAA181 - Dara-VRd Vs Dara-Rd - Testing the Use of Combination Therapy in NDMM

Click here for details


NCT02195479: Phase 3 (ALCYONE) Dara-VMP Vs VMP - Bortezomib, Melphalan, Prednisone & Daratumumab

Click here for details


NCT02541383: Phase 3 (CASSIOPEIA) Dara-VTd Vs VTd - Bortezomib, thalidomide, dex +/-Daratumumab before & after ASCT

Click here for details


NCT02874742: Phase 2 (GRIFFIN) - Dara-VRd Vs VRd - Daratumumab, Len., Bortezomib & Dex in NDMM

Click here for details


NCT04268498: Phase2 (ADVANCE) Dara-KRd - Daratumumab, Carfilzomib, Lenalidomide, Dex NDMM Multiple Myeloma

Click here for details


NCT03290950: Phase 2 (Manhattan) Dara-KRd - A Study of Daratumumab in Patients With NDMM wKRd-D

Click here for details


NCT02252172: Phase 3 (MAIA) Dara-Rd Vs Rd - Dara, Lena & Dex VS Len & Dex in previously untreated Myeloma

Click here for details


NCT03729804: Phase 3 (COBRA) - KRd Vs VRd in Patients with Newly Diagnosed Multiple Myeloma

Click here for details


NCT04096066: Phase 3 KRd Vs Rd - A Trial That Compare Two Treatments TIE - NDMM

Click here for details


NCT01402284: Phase 2 - KRd - Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients

Click here for details

 

NCT04483739: Phase 3 (Iskia) - Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Eligible for ASCT

Click here for details


NCT03319667: Phase 3 (IMROZ) - Isa-VRd Vs VRd - Isatuximab, Bortezomib, Lenalidomide and Dex NDMM

Click here for details


NCT04751877: Phase 3 (IFM2020-05) - Isa-VRd Vs Isa-Rd - Non-Frail NTE Myeloma Elderly Patients

Click here for details

 

NCT05257083: Phase 3 (CARTITUDE-6) DVRd -> Ciltacabtagene Autoleucel Vs DVRd -> Transplant ASCT- NDMM

Click here for details

 

NCT01850524: Phase 3 (TOURMALINE-MM2) Ixa-Rd Vs Rd - Oral Ixazomib + Lenalidomide/Dex Vs Placebo + Len/Dex NDMM

Click here for details

Posts Archive